Please assess the completion status of the following clinical trial:

Trial Title: Radiation Therapy, Cisplatin, Fluorouracil, and Cetuximab in Treating Patients With Locally Advanced Anal Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically confirmed anal cancer~  * Squamous cell disease~ * Locally advanced, non-metastatic disease~ * One of the following clinical TNM stages:~    * T2, N0, M0 (largest diameter ≥ 3 cm)~   * T3-T4, N0, M0~   * Any T, N1-N3, M0~* No undifferentiated small cell carcinoma or adenocarcinoma~* Measurable disease according to RECIST criteria~* Undergone endorectal ultrasound or MRI to evaluate the primary tumor~* Undergone thoraco-abdomino-pelvic scan to evaluate tumor extension~* Disease suitable to receive radiotherapy and chemotherapy~PATIENT CHARACTERISTICS:~* ECOG performance status 0-1~* Leukocytes ≥ 4,000/mm\^3~* ANC ≥ 1,500/mm\^3~* Platelet count ≥ 100,000/mm\^3~* Hemoglobin ≥ 10 g/dL~* Creatinine clearance \> 60 mL/min~* ALT and AST ≤ 5 times upper limit of normal (ULN)~* Alkaline phosphatase ≤ 2.5 times ULN~* Total bilirubin ≤ 1.5 times ULN~* Not pregnant or nursing~* Negative pregnancy test~* No history of cancer within the past 8 years except for in situ cervical cancer or previously treated basal cell carcinoma of the skin~* No contraindications to any component of study therapy~* No serious uncontrolled illness~* No symptomatic grade 1 angina pectoris or angina pectoris ≥ grade 2~* No congestive heart failure~* No peripheral sensory neuropathy~* No uncontrolled diabetes~* No HIV positivity~* No geographical, social, or psychological situations that preclude medical follow up~* Affiliated with a social security system~* No patient deprived of liberty or under trusteeship~PRIOR CONCURRENT THERAPY:~* Patients with a diverting colostomy are eligible~* No prior excision of this tumor~* No prior chemotherapy or radiotherapy for the treatment of this cancer or any other history of radiotherapy or pelvic brachytherapy~* No concurrent coumarin anticoagulants, phenytoin, sorivudine or brivudine, antacids, or allopurinol~* Not registered in another clinical trial with an experimental drug

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).